Fundraising FoxPolaris Partners — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020
Co-investorsPappas CapitalAberdare VenturesEcoR1 CapitalInvus
Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.
Co-investorsMindset VentureOUP (Osage University Partners)
Sonrai Security provides a cloud permissions management platform that enforces least privilege access across cloud identities and services.
AI & Machine LearningCloud ComputingCybersecurityEnterprise SoftwareNew York, US
Brendan Hannigan(Founder)inSandy Bird(Founder)inWilliam Bird(Executive Officer, Director)
BoardDave Barrett(Director)Venky Ganesan(Director)inAlex Doll(Director)in
Co-investorsaVentureMenlo VenturesTen Eleven
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BlackThorn Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.